EcoDrugPlus

Sodium Channel Epithelial 1 Subunit Gamma

Ensembl ID : ENSBMUG00000024583
Gene Symbol: SCNN1G
3 Cross references
155 Possible Orthologues:

Sodium Channel Protein Type 1 Subunit Alpha

Ensembl ID : ENSBMUG00000007756
Gene Symbol: LOC102275090
2 Cross references
136 Possible Orthologues:

Sodium Channel Protein Type 1 Subunit Alpha-Like

Ensembl ID : ENSBMUG00000015642
Gene Symbol: LOC102286276
2 Cross references
137 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 10

Ensembl ID : ENSBMUG00000017414
Gene Symbol: SCN10A
3 Cross references
302 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 11

Ensembl ID : ENSBMUG00000017359
Gene Symbol: SCN11A
3 Cross references
96 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 2

Ensembl ID : ENSBMUG00000011094
Gene Symbol: SCN2A
3 Cross references
130 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSBMUG00000008716
Gene Symbol: SCN3A
3 Cross references
133 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSBMUG00000006304
Gene Symbol: SCN4A
3 Cross references
192 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 5

Ensembl ID : ENSBMUG00000017639
Gene Symbol: SCN5A
3 Cross references
94 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 7

Ensembl ID : ENSBMUG00000007427
Gene Symbol: SCN7A
3 Cross references
85 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSBMUG00000026270
Gene Symbol: SCN8A
3 Cross references
276 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 9

Ensembl ID : ENSBMUG00000007559
Gene Symbol: SCN9A
3 Cross references
109 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).